Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD of Anixa Biosciences Inc from Q3 2016 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Anixa Biosciences Inc quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and change rate from Q3 2016 to Q2 2025.
  • Anixa Biosciences Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 31 Jul 2025 was $15.4M, a 25.5% decline year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

Anixa Biosciences Inc Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $15.4M -$5.28M -25.5% 31 Jul 2025 10-Q 10 Sep 2025
Q1 2025 $14.9M -$7.68M -34% 30 Apr 2025 10-Q 10 Sep 2025
Q4 2024 $16.7M -$6.89M -29.2% 31 Jan 2025 10-Q 28 May 2025
Q3 2024 $18.9M -$4.48M -19.2% 31 Oct 2024 10-Q 10 Sep 2025
Q2 2024 $20.7M -$3.89M -15.8% 31 Jul 2024 10-Q 10 Sep 2025
Q1 2024 $22.6M -$3.33M -12.9% 30 Apr 2024 10-Q 10 Sep 2025
Q4 2023 $23.6M -$3.31M -12.3% 31 Jan 2024 10-Q 28 May 2025
Q3 2023 $23.4M -$4.83M -17.1% 31 Oct 2023 10-Q 10 Sep 2025
Q2 2023 $24.6M -$6.32M -20.5% 31 Jul 2023 10-Q 06 Sep 2024
Q1 2023 $25.9M -$5.49M -17.5% 30 Apr 2023 10-Q 06 Sep 2024
Q4 2022 $26.9M -$6.33M -19% 31 Jan 2023 10-Q 04 Jun 2024
Q3 2022 $28.2M -$6.57M -18.9% 31 Oct 2022 10-K 10 Jan 2025
Q2 2022 $30.9M -$4.95M -13.8% 31 Jul 2022 10-Q 06 Sep 2023
Q1 2022 $31.4M -$5.65M -15.2% 30 Apr 2022 10-Q 06 Sep 2023
Q4 2021 $33.2M +$20.2M +154% 31 Jan 2022 10-Q 14 Jun 2023
Q3 2021 $34.8M +$26.5M +321% 31 Oct 2021 10-K 16 Jan 2024
Q2 2021 $35.9M +$27.7M +341% 31 Jul 2021 10-Q 09 Sep 2022
Q1 2021 $37.1M +$32.2M +668% 30 Apr 2021 10-Q 09 Sep 2022
Q4 2020 $13.1M +$8.08M +162% 31 Jan 2021 10-Q 10 Jun 2022
Q3 2020 $8.26M +$3.45M +71.7% 31 Oct 2020 10-K 04 Jan 2023
Q2 2020 $8.14M +$2.74M +50.7% 31 Jul 2020 10-Q 01 Sep 2021
Q1 2020 $4.82M -$1.35M -21.8% 30 Apr 2020 10-Q 01 Sep 2021
Q4 2019 $5M -$146K -2.83% 31 Jan 2020 10-Q 10 Jun 2021
Q3 2019 $4.81M -$371K -7.16% 31 Oct 2019 10-K 04 Jan 2022
Q2 2019 $5.4M -$765K -12.4% 31 Jul 2019 10-Q 08 Sep 2020
Q1 2019 $6.17M +$149K +2.48% 30 Apr 2019 10-Q 08 Sep 2020
Q4 2018 $5.14M -$1.26M -19.7% 31 Jan 2019 10-Q 09 Jun 2020
Q3 2018 $5.18M -$2.74M -34.6% 31 Oct 2018 10-K 07 Jan 2021
Q2 2018 $6.16M 31 Jul 2018 10-Q 06 Sep 2019
Q1 2018 $6.02M 30 Apr 2018 10-Q 06 Sep 2019
Q4 2017 $6.4M 31 Jan 2018 10-Q 09 Mar 2018
Q3 2017 $7.92M +$6.94M +702% 31 Oct 2017 10-K 09 Jan 2020
Q3 2016 $987K 31 Oct 2016 10-K 11 Jan 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.